Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial

Locke J. Bryan, Carla Casulo, Pamela B. Allen, Scott E. Smith, Hatice Savas, Gary L. Dillehay, Reem Karmali, Barbara Pro, Kaitlyn L. Kane, Latifa A. Bazzi, Joan S. Chmiel, Brett A. Palmer, Jayesh Mehta, Leo I. Gordon, Jane N. Winter*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry